Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
Seer
AddedFeb 15, 2024
UpdatedJun 28, 2026
Seer

Seer

Public

Proteomics tech firm pioneering in efficient nanoparticle-based workflows for large scale plasma and serum analysis.

HQ
Redwood City, CA, US
Founded
2017
Overview
Compare
Fundraising
Employees
Website

Seer is a proteomics technology company dedicated to pioneering efficient nanoparticle-based workflows for large-scale plasma and serum analysis. Their core mission is to decode the secrets of the proteome to improve human health by empowering the scientific community with advanced tools. Seer's flagship product, the Proteographâ„¢ Suite, offers robust and unbiased proteomics services, targeting researchers and institutions focused on deep proteomic analysis.

Seer has made significant strides in the field of proteomics, enabling large-scale plasma and serum analysis for the first time. Their innovative approach has eliminated many technological barriers, allowing proteomics to advance at a pace comparable to genomics and transcriptomics. This breakthrough has had a profound impact on scientific research, driving exceptional scientific outcomes and expanding the possibilities for human health advancements.

Seer - Quick Facts

When was Seer founded?

Seer was founded in 2017.

Where is Seer's headquarters located?

Seer's headquarters is located in Redwood City, CA, US.

When was Seer's last funding round?

Seer's most recent funding round was for $55M (USD) in July 2020.

How much has Seer raised to-date?

As of Jul 22, 2020, Seer has raised a total of $169.5M (USD).

How many employees does Seer have?

Seer has 164 employees as of Feb 6, 2024.

Seer - Classification

Ownership
  • Equity
  • Venture Capital
Technology
  • HealthTech
Geographic Exposure
  • Global
Revenue
  • Recurring
  • Transactional
Customer
  • Enterprise
  • Government
Main Product
  • Biotech
  • Proteomics
Tags
  • Hardware
  • Platform
  • Software
Unique IDs
  • ein: 821153150
  • secCik: 0001726445
  • ticker: SEER
NAICS
  • 540000Professional, Scientific, and Technical Services
  • 541714Research and Development in Biotechnology (except Nanobiotechnology)
  • 541000Professional, Scientific, and Technical Services
  • 541700Scientific Research and Development Services
  • 541710Research and Development in the Physical, Engineering, and Life Sciences
SIC
  • 3820Laboratory Apparatus And Analytical, Optical, Measuring, And Control
  • 3826Laboratory Analytical Instruments
ISIC
  • 2651Manufacture of measuring, testing, navigating and control equipment
Show 25 more industry codes
NAICS
  • 334500Navigational, Measuring, Electromedical, and Control Instruments Manufacturing
  • 334510Navigational, Measuring, Electromedical, and Control Instruments Manufacturing
  • 334516Analytical Laboratory Instrument Manufacturing
  • 513200Software Publishers
  • 541500Computer Systems Design and Related Services
  • 330000Manufacturing
  • 510000Information
  • 620000Health Care and Social Assistance
  • 334000Computer and Electronic Product Manufacturing
  • 513000Publishing Industries
  • 623000Nursing and Residential Care Facilities
  • 513210Software Publishers
  • 541510Computer Systems Design and Related Services
  • 541511Custom Computer Programming Services
SIC
  • 4000Railroad Transportation
  • 7300Business Services
  • 8000Health Services
  • 8700Engineering, Accounting, Research, Management, And Related Services
  • 7370Computer Programming, Data Processing, And Other Computer Related
  • 8040Offices And Clinics Of Other Health Practitioners
  • 8730Research, Development, And Testing Services
  • 7371Computer Programming Services
  • 7372Prepackaged Software
  • 8049Offices And Clinics Of Health Practitioners, Not Elsewhere Classified
  • 8731Commercial Physical and Biological Research